Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 12/20 | 0.51 |
| ▸ | F3 | P13726 | 12/20 | 0.51 |
| ▸ | F2 | P00734 | 11/20 | 0.51 |
| ▸ | CFTR | P13569 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846590 | 0.85 | F7 (0.53) | F7F3F2CFTR | |
| SCHEMBL5847598 | 0.80 | F2 (0.50) | F7F3F2CFTRALDH1A1 | |
| SCHEMBL5846804 | 0.78 | F7 (0.59) | F7F3F2 | |
| SCHEMBL6794077 | 0.72 | F7 (0.44) | F7F3F2ALDH1A1GAA | |
| SCHEMBL5846166 | 0.71 | F2 (0.50) | F7F3F2CFTRALDH1A1 | |
| SCHEMBL5846627 | 0.70 | F7 (0.56) | F7F3F2CFTR | |
| SCHEMBL2145480 | 0.70 | F7 (0.65) | F7F3F2 | |
| SCHEMBL23460607 | 0.68 | F7 (0.63) | F7F3F2 | |
| SCHEMBL5848054 | 0.66 | F7 (0.67) | F7F3F2 | |
| SCHEMBL5847557 | 0.65 | F7 (0.52) | F7F3F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005075469-A1 | THIAZOLYL-HYDROXAMIC ACIDS AND THIADIAZOLYL-HYDROXAMIC ACIDS, AND USE THEREOF FOR TREATING DISEASES ASSOCIATED WITH HISTONE DEACETYLASE ENZYMATIC ACTIVITY | ARGENTA DISCOVERY LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
| US-6908919-B2 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040006230-A1 | Useful as inhibitors of serine proteases; for therapy and prophylaxis of thrombotic conditions including coronary artery and cerebrovascular diseases | PHARMACIA CORPORATION | 2004-01-08 | — | — | US | disclosed |
| EP-1292579-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001087854-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006230-A1 | Useful as inhibitors of serine proteases; for therapy and prophylaxis of thrombotic conditions including coronary artery and cerebrovascular diseases | PRSS1, SERPINC1, SERPINE1 | F7 196/4885F3 100/4885F2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.